XOMA vs NUVL vs PRAX vs PFE

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Pfizer Inc. (PFE) offers the better valuation at 18. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 18. 9x versus XOMA Royalty Corp. at 28. 7x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +461. 5%, compared to -14. 9% for Praxis Precision Medicines, Inc. (PRAX). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus PRAX's -20. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 49β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 185% more volatile than PFE relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 7x forward P/E versus 53. 3x for XOMA Royalty Corp. — 44. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 66. 3% to $548. 80.

In this comparison, PFE (6.

7% yield), XOMA (0. 7% yield) pay a dividend. NUVL, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 6. 7% yield). Both have compounded well over 10 years (PFE: +28. 5%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XOMA is a small-cap high-growth stock; NUVL is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. XOMA, PFE pay a dividend while NUVL, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.